Need immediate assistance? Call 1-518-730-0559 (Us-Canada Toll Free) or Contact Us

 

Acute Agitation and Aggression Treatment Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 – 2027

Table of Content

1 Preface
    1.1 Market Definition and Scope
    1.2 Market Segmentation
    1.3 Key Research Objectives
    1.4 Research Highlights 
2 Assumptions and Acronyms
3 Research Methodology
4 Executive Summary
5 Market Overview

    5.1 Product Overview
    5.2 Market Dynamics
        5.2.1 Drivers
            5.2.1.1 Increase in incidence of dementia in geriatric population 
            5.2.1.2 Rise in burden of mental illness and increase in agitation in patients
            5.2.1.3 Economic burden of schizophrenia
            5.2.1.4 Focus on creating awareness about agitation and aggression
            5.2.1.5 Surge in prescriptions of anti-psychotics
        5.2.2 Restraints
            5.2.2.1 Social stigma associated with mental illness
            5.2.2.2 Preference for non-pharmacological interventions
        5.2.3 Opportunities
            5.2.3.1 Ongoing research on the development of novel treatment for agitation
            5.2.3.2 Agitation and Aggression – Unmet clinical needs
        5.2.4 Global Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, 2017–2027
        5.2.5 Global Acute Agitation and Aggression Treatment Market Outlook
        5.2.6 Pipeline Analysis
        5.2.7 Regulatory Scenario Assessment
        5.2.8 Treatment Protocol
        5.2.9 Key Strategies adopted by Market Players
        5.2.10 Mental Health Spending
        5.2.11 Healthcare Industry Overview
6 Global Acute Agitation and Aggression Treatment Market Analysis, by Drug Class
    6.1 Introduction
    6.2 Market Value Share Analysis, by Drug Class 
    6.3 Market Value Forecast, by Drug Class, 2017–2027
        6.3.1 First-generation Anti-psychotics
        6.3.2 Second-generation Anti-psychotics
        6.3.3 Benzodiazepines
        6.3.4 Others
    6.4 Market Attractiveness, by Drug Class
7 Global Acute Agitation and Aggression Treatment Market Analysis, by Route of Administration
    7.1 Introduction
    7.2 Market Value Share Analysis, by Route of Administration
    7.3 Market Value Forecast, by Route of Administration, 2017–2027
        7.3.1 Oral
        7.3.2 Intramuscular
        7.3.3 Others
    7.4 Market Attractiveness, by Route of Administration
8 Global Acute Agitation and Aggression Treatment Market Analysis, by Indication
    8.1 Introduction
    8.2 Market Value Share Analysis, by Indication
    8.3 Market Value Forecast, by Indication, 2017–2027
        8.3.1 Schizophrenia
        8.3.2 Dementia
        8.3.3 Bipolar Disorders
        8.3.4 Depression
        8.3.5 Alcohol Withdrawal
        8.3.6 Drug-induced Agitation and Aggression
        8.3.7 Others
    8.4 Market Attractiveness, by Indication
9 Global Acute Agitation and Aggression Treatment Market Analysis, by End-user
    9.1 Introduction
    9.2 Market Value Share Analysis, by End-user
    9.3 Market Value Forecast, by End-user, 2017–2027
        9.3.1 Hospitals & Ambulatory Surgical Centers
            9.3.1.1 Intensive Care Unit
            9.3.1.2 Emergency Department
        9.3.2 Psychiatric Care Facilities
        9.3.3 Others
    9.4 Market Attractiveness, by End-user
10 Global Acute Agitation and Aggression Treatment Market Analysis, by Region
    10.1 Regional Outlook
    10.2 Global Scenario
    10.3 Introduction
    10.4 Market Value Share Analysis, by Region
        10.4.1 North America
        10.4.2 Europe
        10.4.3 Latin America
        10.4.4 Asia Pacific 
        10.4.5 Middle East & Africa
    10.5 Market Attractiveness Analysis, by Region
11 North America Acute Agitation and Aggression Treatment Market Analysis
    11.1 Key Findings
    11.2 Market Value Forecast, by Country, 2017–2027
        11.2.1 U.S.
        11.2.2 Canada
    11.3 Market Value Forecast, by Drug Class, 2017–2027
        11.3.1 First-generation Anti-psychotics
        11.3.2 Second-generation Anti-psychotics
        11.3.3 Benzodiazepines
        11.3.4 Others
    11.4 Market Value Forecast, by Route of Administration, 2017–2027
        11.4.1 Oral
        11.4.2 Intramuscular
        11.4.3 Others
    11.5 Market Value Forecast, by Indication, 2017–2027
        11.5.1 Schizophrenia
        11.5.2 Dementia
        11.5.3 Bipolar Disorders
        11.5.4 Depression
        11.5.5 Alcohol Withdrawal
        11.5.6 Drug-induced Agitation and Aggression
        11.5.7 Others
    11.6 Market Value Forecast, by End-user, 2017–2027
        11.6.1 Hospitals & Ambulatory Surgical Centers
            11.6.1.1 Intensive Care Unit
            11.6.1.2 Emergency Department
        11.6.2 Psychiatric Care Facilities
        11.6.3 Others
    11.7 Market Attractiveness Analysis
        11.7.1 By Country
        11.7.2 By Drug Class
        11.7.3 By Route of Administration
        11.7.4 By Indication
        11.7.5 By End-user
12 Europe Acute Agitation and Aggression Treatment Market Analysis
    12.1 Key Findings
    12.2 Market Value Forecast, by Country/Sub-region, 2017–2027
        12.2.1 U.K.
        12.2.2 Germany
        12.2.3 France
        12.2.4 Italy
        12.2.5 Spain
        12.2.6 Rest of Europe
    12.3 Market Value Forecast, by Drug Class, 2017–2027
        12.3.1 First-generation Anti-psychotics
        12.3.2 Second-generation Anti-psychotics
        12.3.3 Benzodiazepines
        12.3.4 Others
    12.4 Market Value Forecast, by Route of Administration, 2017–2027
        12.4.1 Oral
        12.4.2 Intramuscular
        12.4.3 Others
    12.5 Market Value Forecast, by Indication, 2017–2027
        12.5.1 Schizophrenia
        12.5.2 Dementia
        12.5.3 Bipolar Disorders
        12.5.4 Depression
        12.5.5 Alcohol Withdrawal
        12.5.6 Drug-induced Agitation and Aggression
        12.5.7 Others
    12.6 Market Value Forecast, by End-user, 2017–2027
        12.6.1 Hospitals & Ambulatory Surgical Centers
            12.6.1.1 Intensive Care Unit
            12.6.1.2 Emergency Department
        12.6.2 Psychiatric Care Facilities
        12.6.3 Others
    12.7 Market Attractiveness Analysis
        12.7.1 By Country/Sub-region
        12.7.2 By Drug Class
        12.7.3 By Route of Administration
        12.7.4 By Indication
        12.7.5 By End-user
13 Asia Pacific Acute Agitation and Aggression Treatment Market Analysis
    13.1 Key Findings
    13.2 Market Value Forecast, by Country/Sub-region, 2017–2027
        13.2.1 China
        13.2.2 Japan
        13.2.3 India
        13.2.4 Australia
        13.2.5 Rest of Asia Pacific
    13.3 Market Value Forecast, by Drug Class, 2017–2027
        13.3.1 First-generation Anti-psychotics
        13.3.2 Second-generation Anti-psychotics
        13.3.3 Benzodiazepines
        13.3.4 Others
    13.4 Market Value Forecast, by Route of Administration, 2017–2027
        13.4.1 Oral
        13.4.2 Intramuscular
        13.4.3 Others
    13.5 Market Value Forecast, by Indication, 2017–2027
        13.5.1 Schizophrenia
        13.5.2 Dementia
        13.5.3 Bipolar Disorders
        13.5.4 Depression
        13.5.5 Alcohol Withdrawal
        13.5.6 Drug-induced Agitation and Aggression
        13.5.7 Others
    13.6 Market Value Forecast, by End-user, 2017–2027
        13.6.1 Hospitals & Ambulatory Surgical Centers
            13.6.1.1 Intensive Care Unit
            13.6.1.2 Emergency Department
        13.6.2 Psychiatric Care Facilities
        13.6.3 Others
    13.7 Market Attractiveness Analysis
        13.7.1 By Country/Sub-region
        13.7.2 By Drug Class
        13.7.3 By Route of Administration
        13.7.4 By Indication
        13.7.5 By End-user
14 Latin America Acute Agitation and Aggression Treatment Market Analysis
    14.1 Key Findings
    14.2 Market Value Forecast, by Country/Sub-region, 2017–2027
        14.2.1 Brazil
        14.2.2 Mexico
        14.2.3 Rest of Latin America
    14.3 Market Value Forecast, by Drug Class, 2017–2027
        14.3.1 First-generation Anti-psychotics
        14.3.2 Second-generation Anti-psychotics
        14.3.3 Benzodiazepines
        14.3.4 Others
    14.4 Market Value Forecast, by Route of Administration, 2017–2027
        14.4.1 Oral
        14.4.2 Intramuscular
        14.4.3 Others
    14.5 Market Value Forecast, by Indication, 2017–2027
        14.5.1 Schizophrenia
        14.5.2 Dementia
        14.5.3 Bipolar Disorders
        14.5.4 Depression
        14.5.5 Alcohol Withdrawal
        14.5.6 Drug-induced Agitation and Aggression
        14.5.7 Others
    14.6 Market Value Forecast, by End-user, 2017–2027
        14.6.1 Hospitals & Ambulatory Surgical Centers
            14.6.1.1 Intensive Care Unit
            14.6.1.2 Emergency Department
        14.6.2 Psychiatric Care Facilities
        14.6.3 Others
    14.7 Market Attractiveness Analysis
        14.7.1 By Country/Sub-region
        14.7.2 By Drug Class
        14.7.3 By Route of Administration
        14.7.4 By Indication
        14.7.5 By End-user
15 Middle East & Africa Acute Agitation and Aggression Treatment Market Analysis
    15.1 Key Findings
    15.2 Market Value Forecast, by Country/Sub-region, 2017–2027
        15.2.1 GCC Countries
        15.2.2 Israel
        15.2.3 South Africa
        15.2.4 Rest of Middle East & Africa
    15.3 Market Value Forecast, by Drug Class, 2017–2027
        15.3.1 First-generation Anti-psychotics
        15.3.2 Second-generation Anti-psychotics
        15.3.3 Benzodiazepines
        15.3.4 Others
    15.4 Market Value Forecast, by Route of Administration, 2017–2027
        15.4.1 Oral
        15.4.2 Intramuscular
        15.4.3 Others
    15.5 Market Value Forecast, by Indication, 2017–2027
        15.5.1 Schizophrenia
        15.5.2 Dementia
        15.5.3 Bipolar Disorders
        15.5.4 Depression
        15.5.5 Alcohol Withdrawal
        15.5.6 Drug-induced Agitation and Aggression
        15.5.7 Others
    15.6 Market Value Forecast, by End-user, 2017–2027
        15.6.1 Hospitals & Ambulatory Surgical Centers
            15.6.1.1 Intensive Care Unit
            15.6.1.2 Emergency Department
        15.6.2 Psychiatric Care Facilities
        15.6.3 Others
    15.7 Market Attractiveness Analysis
        15.7.1 By Country/Sub-region
        15.7.2 By Drug Class
        15.7.3 By Route of Administration
        15.7.4 By Indication
        15.7.5 By End-user
16 Company Profiles
    16.1 Eli Lilly and Company 
        16.1.1 Company Overview (Headquarters, Business Segments, Employee Strength)
        16.1.2 Financial Overview
        16.1.3 SWOT Analysis
        16.1.4 Strategic Overview
    16.2 Pfizer, Inc. 
        16.2.1 Company Overview (Headquarters, Business Segments, Employee Strength)
        16.2.2 Financial Overview
        16.2.3 SWOT Analysis
        16.2.4 Strategic Overview
    16.3 Ono Pharmaceutical Co., Ltd. 
        16.3.1 Company Overview (Headquarters, Business Segments, Employee Strength)
        16.3.2 Financial Overview
        16.3.3 SWOT Analysis
        16.3.4 Strategic Overview
    16.4 Otsuka Holdings Co., Ltd. 
        16.4.1 Company Overview (Headquarters, Business Segments, Employee Strength)
        16.4.2 Financial Overview
        16.4.3 SWOT Analysis
        16.4.4 Strategic Overview
    16.5 GlaxoSmithKline plc
        16.5.1 Company Overview (Headquarters, Business Segments, Employee Strength)
        16.5.2 Financial Overview
        16.5.3 SWOT Analysis
        16.5.4 Strategic Overview
    16.6 Bristol-Myers Squibb Company 
        16.6.1 Company Overview (Headquarters, Business Segments, Employee Strength)
        16.6.2 Financial Overview
        16.6.3 SWOT Analysis
        16.6.4 Strategic Overview
    16.7 Janssen Biotech, Inc. (Johnson & Johnson)
        16.7.1 Company Overview (Headquarters, Business Segments, Employee Strength)
        16.7.2 Financial Overview
        16.7.3 SWOT Analysis
        16.7.4 Strategic Overview
    16.8 H. Lundbeck A/S 
        16.8.1 Company Overview (Headquarters, Business Segments, Employee Strength)
        16.8.2 Financial Overview
        16.8.3 SWOT Analysis
        16.8.4 Strategic Overview

Custom Market Research Services

MRRSE offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Get A Free Custom Research Quote